PIN A1
Alternative Names: PIN-A1Latest Information Update: 18 Dec 2024
At a glance
- Originator Pin Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Casein kinase lalpha degraders; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 23 Oct 2024 Preclinical trials in Solid tumours in South Korea (Intraperitoneal) before October 2024 (Pin Therapeutics pipeline, December 2024)
- 23 Oct 2024 Pharmacokinetics, pharmacodynamics and adverse events data from the preclinical trial in Solid tumors and Acute myeloid leukemia presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 13 Dec 2022 PIN A1 is available for licensing as of 08 Dec 2022. https://www.pintherapeutics.com/eng/company/collaborator.html